A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
Public ClinicalTrials.gov record NCT06395090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
Study identification
- NCT ID
- NCT06395090
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Favezelimab Biological
- Favezelimab/Pembrolizumab Biological
- Vibostolimab Biological
- Pembrolizumab/Vibostolimab Biological
Biological
Eligibility (public fields only)
- Age range
- Up to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2025
- Primary completion
- Jun 29, 2029
- Completion
- Jun 29, 2029
- Last update posted
- Apr 7, 2025
2025 – 2029
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale-New Haven Hospital ( Site 2012) | New Haven | Connecticut | 06510 | — |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 2017) | Iowa City | Iowa | 52242 | — |
| Children's Mercy Hospital ( Site 2024) | Kansas City | Missouri | 64108 | — |
| Rutgers Cancer Institute of New Jersey ( Site 2008) | New Brunswick | New Jersey | 08903 | — |
| New York Medical College ( Site 2023) | Valhalla | New York | 10595 | — |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2003) | Fargo | North Dakota | 58122 | — |
| Children's Hospital of Philadelphia (CHOP) ( Site 2021) | Philadelphia | Pennsylvania | 19104 | — |
| Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 2015) | Sioux Falls | South Dakota | 57105 | — |
| Intermountain - Primary Children's Hospital ( Site 2014) | Salt Lake City | Utah | 84113 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06395090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06395090 live on ClinicalTrials.gov.